Market research
ARGX.BR argenx SE
BR EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 56B
- P/E ratio
- 40.16
- Analyst target
- 934.5408
- Dividend yield
- Not available
- Beta
- -0.04
Profile
Company facts
- Exchange
- BR
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL0010832176
- Market cap
- 56B
- P/E ratio
- 40.16
- Analyst target
- 934.5408
- Dividend yield
- Not available
- Beta
- -0.04
About
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ARGX.BR discussion.
5 years, 5 months ago
argenx SE is currently in a long term uptrend where the price is trading 6.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 300.7.
argenx SE's total revenue sank by 70.8% to $8M since the same quarter in the previous year.
Its net income has dropped by 33.8% to $-158M since the same quarter in the previous year.
Finally, its free cash flow fell by 246.5% to $-136M since the same quarter in the previous year.
Based on the above factors, argenx SE gets an overall score of 2/5.